Machine Learning Ensemble for Bladder Cancer Chemotherapy Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current systems for predicting chemotherapy outcomes in bladder cancer are limited by reliance on empirical data and histological findings, and existing computational methods often suffer from inherent biases and assumptions, leading to inaccurate predictions and failure to account for in vivo environments.
Innovation Solution
A predictive model for high-grade bladder cancer treatment outcomes is developed using a collection of machine learning algorithms trained on omics data, selecting models with high accuracy gain and weighting factors to improve prediction accuracy, specifically utilizing RNA transcription values for genes like PCDHGA4 and HSP90AB2P to calculate treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If computational systems based on cell culture data and single models are used to predict treatment outcome, then predictive power is provided in certain circumstances, but the system does not fully reflect in vivo environments and relies on specific model assumptions
Solution Approach 1:
The patent combines multiple machine learning models (support vector machines, random forests, neural networks, etc.) with diverse omics data types (genomics, transcriptomics, proteomics, metabolomics) to create an integrated prediction system. This merging of multiple data sources and algorithms provides both predictive power and reflects the complexity of in vivo environments through multi-omics integration
2Productivity
If machine learning algorithms with built-in assumptions are used for predictive analysis, then pattern recognition in large data sets is achieved, but the inherent bias of each algorithm may not be valid for the specific disease and/or drug treatment
Solution Approach 1:
The system merges multiple machine learning algorithms with different underlying assumptions and approaches. By ensembling diverse algorithms (supervised, unsupervised, semi-supervised learning methods), the system processes large omics datasets efficiently while reducing the impact of any single algorithm's inherent biases, thereby improving overall prediction accuracy for the specific disease context
Solution Approach 2:
The system dynamically adjusts model parameters and selection based on the specific characteristics of the disease and treatment being analyzed. Through cross-validation and performance metrics, the system optimizes which algorithms and parameters are most valid for the specific bladder cancer treatment context, rather than using fixed assumptions
3Productivity
If models maximized for a particular prediction are used, then the prediction outcome is obtained, but the accuracy may not be the best as compared to a random event and/or other models
Solution Approach 1:
The system implements cross-validation and performance evaluation metrics to provide feedback on model accuracy. By testing models on held-out validation sets and comparing performance against random chance, the system identifies which maximized models truly provide superior accuracy rather than overfitting to training data
Solution Approach 2:
The system combines multiple models through ensembling techniques, where the final prediction integrates results from multiple maximized models. This merging approach ensures that the overall system achieves better accuracy than any single model alone, while maintaining efficient prediction through the coordinated work of multiple specialized models
Data Source
AI summary
Contemplated systems and methods allow for prediction of chemotherapy outcome for patients diagnosed with high-grade bladder cancer. In particularly preferred aspects, the prediction is performed using a model based on machine learning wherein the model has a minimum predetermined accuracy gain and wherein a thusly identified model provides the identity and weight factors for omics data used in the outcome prediction.